Letter to the editor

Recent update on biological activities and pharmacological actions of liraglutide

Juhi Tiwari1, Gaurav Gupta1[*],2, Rajiv Dahiya3, Kavita Pabreja2, Rakesh Kumar Sharma4, Anurag Mishra4, Kamal Dua5,6,7

1School of Pharmacy, Jaipur National University, Jagatpura 302017, Jaipur, India

2School of Medicine and Public Health, University of Newcastle, Newcastle, NSW 2308, Australia

3Laboratory of Peptide Research and Development, School of Pharmacy, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad & Tobago, West Indies

4School of Pharmacy, Suresh Gyan Vihar University, Jagatpura 302017, Jaipur, India

5Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia

6School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW 2308, Australia

7School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, 173229, India

EXCLI J 2017;16:Doc742

 

Dear Editor,

Liraglutide (LG), an analog of human glucagon-like peptide 1 (GLP-1), has been permitted for type 2 diabetes therapy. LG triggers the GLP-1 receptor, leading to release of insulin in the presence of high glucose concentrations, it declines secretion of glucagon in a glucose-dependent manner and directly applying to the β cells of pancreas to help its proliferation and differentiation (Dharmalingam et al., 2011[11]; Drucker et al., 2010[12]). The mechanism of lowering blood glucose also includes a delay in gastric emptying. LG is approved by the European Medicines Agency (EMA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010, for the treatment of type 2 diabetes mellitus (T2DM) (Ye et al., 2017[48]). A number of studies suggest that LG, GLP-1 has additional benefits (Zhang et al., 2017[49]). Here we have reviewed various pharmacological actions of LG (Table 1(Tab. 1)). (References in Table 1: Li et al., 2017[32]; Qi et al., 2017[43]; Feng et al., 2017[13]; Garg et al., 2017[14]; King et al., 2017[26]; Hu et al., 2017[16]; Badawi et al., 2017[4]; le Roux et al., 2017[30]; Mezquita-Raya et al., 2017[39]; Martinez et al., 2017[37]; Anholm et al., 2017[2]; Kumarathurai et al., 2017[27]; Hunt et al., 2017[18]; Iacobellis et al., 2017[20]; von Scholten et al., 2017[45]; Manigault and Thurston, 2016[35]; Palleria et al., 2017[40]; Ishii et al., 2017[21]; Bisgaard et al., 2016[5]; Abdelsameea et al., 2017[1]; Jennings et al., 2016[22]; Chen et al., 2016[9]; Dejgaard et al., 2017[10]; Bouchi et al., 2017[6]; Li et al., 2016[33]; Hvistendahl et al., 2016[19]; Bouchi et al., 2017[6]; Arturi et al., 2016[3]; Kumarathurai et al., 2017[28]; Ke et al., 2016[25]; Zhou et al., 2016[50]; Zobel et al., 2017[51]; Calvo Gomez et al., 2016[7]; Petit et al., 2017[41]; Kaur et al., 2016[24]; Mansur et al., 2017[36]; Wang et al., 2016[46]; Hu et al., 2016[17]; Lee et al., 2016[31]; Pra et al., 2016[42]; Langlois et al., 2016[29]; Mathieu et al., 2016[38]; Wang et al., 2016[47]; Saponaro et al., 2016[44]; Li et al., 2016[34]; Htike et al., 2016[15]; Kato et al., 2016[23]; Chai et al., 2016[8].)

 

References

1. Abdelsameea AA, Abbas NA, Abdel Raouf SM. Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers. Naunyn Schmiedeberg's Arch Pharmacol. 2017;390:311-9.
2. Anholm C, Kumarathurai P, Pedersen LR, Nielsen OW, Kristiansen OP, Fenger M, et al. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. Diabetes Obes Metab. 2017;10.1111/dom.12891.
3. Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine. 2016;epub ahead of print. 10.1007/s12020-016-1166-4.
4. Badawi GA, Abd El Fattah MA, Zaki HF, El Sayed MI. Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease. Inflammopharmacology. 2017;epub ahead of print. 10.1007/s10787-017-0331-6.
5. Bisgaard LS, Bosteen MH, Fink LN, Sorensen CM, Rosendahl A, Mogensen CK, et al. Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr-/- mice. PLoS One. 2016;11(12):e0168396.
6. Bouchi R, Nakano Y, Fukuda T, Takeuchi T, Murakami M, Minami I, et al. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocr J. 2017;64:269-81.
7. Calvo Gomez C, Gomez-Huelgas R, Lima Ruiz J, Masmiquel Comas L, Michan Dona A, Zapatero Gaviria A. Expert consensus on the use of liraglutide in the treatment of diabetes in internal medicine. Int J Clin Pharmacol Ther. 2016;54:880-90.
8. Chai W, Fu Z, Aylor KW, Barrett EJ, Liu Z. Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats. Am J Physiol. 2016;311:E640-8.
9. Chen WR, Chen YD, Tian F, Yang N, Cheng LQ, Hu SY, et al. Effects of liraglutide on reperfusion injury in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Imaging. 2016;9(12):e005146.
10. Dejgaard TF, Johansen NB, Frandsen CS, Asmar A, Tarnow L, Knop FK, et al. Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes Obes Metab. 2017;19:734-8.
11. Dharmalingam M, Sriram U, Baruah MP. Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian J Endocrinol Metab. 2011;15:9-17.
12. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov. 2010;9:267-8.
13. Feng W, Gao C, Bi Y, Wu M, Li P, Shen S, et al. A randomized trial comparing gliclazide, liraglutide, and metformin effects on diabetes with nonalcoholic fatty liver disease. J Diabetes. 2017;epub ahead of print. 10.1111/1753-0407.12555.
14. Garg M, Ghanim H, Kuhadiya ND, Green K, Hejna J, Abuaysheh S, et al. Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes. Diabetes Obes Metab. 2017;epub ahead of print. 10.1111/dom.12944.
15. Htike ZZ, Yates T, Brady EM, Webb D, Gray LJ, Swarbrick D, et al. Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). Cardiovasc Diabetol. 2016;15(1):102.
16. Hu SY, Zhang Y, Zhu PJ, Zhou H, Chen YD. Liraglutide directly protects cardiomyocytes against reperfusion injury possibly via modulation of intracellular calcium homeostasis. J Geriatr Cardiol. 2017;14:57-66.
17. Hu XK, Yin XH, Zhang HQ, Guo CF, Tang MX. Liraglutide attenuates the osteoblastic differentiation of MC3T3E1 cells by modulating AMPK/mTOR signaling. Mol Med Rep. 2016;14:3662-8.
18. Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes Obes Metab. 2017;epub ahead of print. 10.1111/dom.12890.
19. Hvistendahl M, Brandt CF, Tribler S, Naimi RM, Hartmann B, Holst JJ, et al. Effect of liraglutide treatment on jejunostomy output in patients with short bowel syndrome: an open-label pilot study. JPEN J Parenter Enteral Nutr. 2016;epub ahead of print. 0.1177/0148607116672265.
20. Iacobellis G, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. Obesity (Silver Spring). 2017;25:311-6.
21. Ishii H, Niiya T, Ono Y, Inaba N, Jinnouchi H, Watada H. Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study. Diabetol Metab Syndr. 2017;9:3.
22. Jennings L, Nestor L, Molloy O, Hughes R, Moriarty B, Kirby B. The treatment of hidradenitis suppurativa with the glucagon-like peptide -1 agonist liraglutide. Br J Dermatol. 2016;epub ahead of print. 10.1111/bjd.15233.
23. Kato T, Iizuka K, Niwa H, Takeda J. Liraglutide improved glycaemic instability in a patient with diabetes with insulin antibodies. BMJ Case Rep. 2016;2016.
24. Kaur P, Mahendru S, Mithal A. Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting. Indian J Endocrinol Metab. 2016;20:595-9.
25. Ke J, Wei R, Yu F, Zhang J, Hong T. Liraglutide restores angiogenesis in palmitate-impaired human endothelial cells through PI3K/Akt-Foxo1-GTPCH1 pathway. Peptides. 2016;86:95-101.
26. King AB, Philis-Tsimikas A, Kilpatrick ES, Langbakke IH, Begtrup K, Vilsboll T. A fixed ratio combination of insulin degludec and liraglutide (IDegLira) reduces glycemic fluctuation and brings more patients with Type 2 diabetes within blood glucose target ranges. Diabetes Technol Ther. 2017;19:255-64.
27. Kumarathurai P, Anholm C, Fabricius-Bjerre A, Nielsen OW, Kristiansen O, Madsbad S, et al. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study. J Hypertens. 2017;35:1070-8.
28. Kumarathurai P, Anholm C, Larsen BS, Olsen RH, Madsbad S, Kristiansen O, et al. Effects of liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebo-controlled crossover study. Diabetes Care. 2017;40:117-24.
29. Langlois A, Dal S, Vivot K, Mura C, Seyfritz E, Bietiger W, et al. Improvement of islet graft function using liraglutide is correlated with its anti-inflammatory properties. Br J Pharmacol. 2016;173:3443-53.
30. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DC, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-409.
31. Lee MY, Tsai KB, Hsu JH, Shin SJ, Wu JR, Yeh JL. Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways. Sci Rep. 2016;6:31788.
32. Li J, Su L, Gong YY, Ding ML, Hong SB, Yu S, et al. Downregulation of miR-139-5p contributes to the antiapoptotic effect of liraglutide on the diabetic rat pancreas and INS-1 cells by targeting IRS1. PLoS One. 2017;12(3):e0173576.
33. Li LR, Jia XL, Hui H, Zhang J, Liu Y, Cui WJ, et al. Liraglutide enhances the efficacy of human mesenchymal stem cells in preserving islet beta-cell function in severe non-obese diabetic mice. Mol Med. 2016;epub ahead of print. 10.2119/molmed.2016.00168.
34. Li N, Zhao Y, Yue Y, Chen L, Yao Z, Niu W. Liraglutide ameliorates palmitate-induced endothelial dysfunction through activating AMPK and reversing leptin resistance. Biochem Biophys Res Commun. 2016;478:46-52.
35. Manigault KR, Thurston MM. Liraglutide: a glucagon-like peptide-1 agonist for chronic weight management. Consult Pharm. 2016;31:685-97.
36. Mansur RB, Ahmed J, Cha DS, Woldeyohannes HO, Subramaniapillai M, Lovshin J, et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. J Affect Disord. 2017;207:114-20.
37. Martinez L, Penfornis A, Gautier JF, Eschwege E, Charpentier G, Bouzidi A, et al. Effectiveness and persistence of liraglutide treatment among patients with Type 2 diabetes treated in primary care and specialist settings: a subgroup analysis from the evidence study, a prospective, 2-year follow-up, observational, post-marketing study. Adv Ther. 2017;34:674-85.
38. Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, et al. Efficacy and safety of liraglutide added to insulin treatment in Type 1 diabetes: the adjunct one treat-to-target randomized trial. Diabetes Care. 2016;39:1702-10.
39. Mezquita-Raya P, Ramirez de Arellano A, Kragh N, Vega-Hernandez G, Pohlmann J, Valentine WJ, et al. Liraglutide versus lixisenatide: long-term cost-effectiveness of GLP-1 receptor agonist therapy for the treatment of Type 2 diabetes in Spain. Diabetes Ther. 2017;8:401-15.
40. Palleria C, Leo A, Andreozzi F, Citraro R, Iannone M, Spiga R, et al. Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects. Behav Brain Res. 2017;321:157-69.
41. Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study. J Clin Endocrinol Metab. 2017;102:407-15.
42. Pra M, Ferreira GK, de Mello AH, Schraiber RB, Cardoso LC, Souza LD, et al. Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult rats. Biochem Cell Biol. 2016;94:451-8.
43. Qi L, Chen Z, Wang Y, Liu X, Liu X, Ke L, et al. Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3beta. Am J Transl Res. 2017;9:247-60.
44. Saponaro F, Sonaglioni A, Rossi A, Montefusco L, Lombardo M, Adda G, et al. Improved diastolic function in type 2 diabetes after a six month liraglutide treatment. Diabetes Res Clin Pract. 2016;118:21-8.
45. von Scholten BJ, Persson F, Rosenlund S, Eugen-Olsen J, Pielak T, Faber J, et al. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab. 2017;epub ahead of print. 10.1111/dom.12884.
46. Wang L, Li P, Tang Z, Yan X, Feng B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci Rep. 2016;6:33251.
47. Wang XW, Zhang FX, Yang F, Ding ZF, Agarwal N, Guo ZK, et al. Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro. Acta Pharmacol Sin. 2016;37:1349-58.
48. Ye X, Qi J, Yu D, Wu Y, Zhu S, Li S, et al. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes. J Diabetes Complications. 2017;31:726-34.
49. Zhang Y, Ling Y, Yang L, Cheng Y, Yang P, Song X, et al. Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat. Mol Cell Endocrinol. 2017;448:98-107.
50. Zhou F, Zhang Y, Chen J, Hu X, Xu Y. Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol. 2016;791:735-40.
51. Zobel EH, von Scholten BJ, Lindhardt M, Persson F, Hansen TW, Rossing P. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. J Diabetes Complications. 2017;31:162-8.
 
 
 

Table 1: Recent update on biological activities and pharmacological actions of liraglutide

[*] Corresponding Author:

Dr. Gaurav Gupta, School of Pharmacy, Jaipur National University, Jagatpura 302017, Jaipur, India; Contact number: +91 7014790412, eMail: gauravpharma25@gmail.com